To explore the serological indexes of HCV complicated with HBV infection, and to explore the clinical significance by analyzing the mixed infection of genotype.

The levels of anti-HCV and serological test of anti-HBV of 431 cases with HCV infection were tested by ELISA, then the results were confirmed by chemiluminescence immunoassay particles. Total of 60 cases with HCV and HBV co-infection were taken as treatment group, the 60 cases with HCV infection were as control group. The levels of HCV RNA and HBV DNA loads of 60 cases with HCV and HBV co-infection were detected by real-time fluorescence quantitative polymerase chain reaction (PCR), while the genotyping and related biochemical indicators of HCV and HBV were detected, respectively.

Among the experimental group and the control group, patients with viral load higher than 1 × 10⁵ copies/ml were 68.33% (41/60) and 31.67% (19/60), respectively, with significant difference (F = 35.35, P = 0.0403). The cases in the experimental group of the three subtypes of HCV (1b, 2a and 6a) were 71.67% (43/60), 26.67% (16/60) and 1.67% (1/60), respectively; while the patients with C and B genotypes in HBV subtypes were 83.33% (50/60) and 41.67% (25/60), with significant difference (F = 38.15, P = 0.0326). The positive rates of transaminase increasing were 56.67% (34/60) and 25.00% (15/60) in the experimental group and the control group, with significant difference (F = 40.65, P = 40.65).

The genotype of HBV is mainly C after HCV and HBV co-infection, and the level of anti-HCV level is not affected. HBV infection is inhibited by HCV. HCV and HBV co-infection might increase the risk of hepatocellular carcinoma.